middle.news
Can Control Bionics’ $2.06M Rights Issue Propel NeuroStrip® to Market Success?
8:31am on Thursday 4th of September, 2025 AEST
•
Healthcare
Read Story
Can Control Bionics’ $2.06M Rights Issue Propel NeuroStrip® to Market Success?
8:31am on Thursday 4th of September, 2025 AEST
Key Points
1-for-5 rights issue at 3.5 cents per share to raise up to $2.06 million
Funds targeted for NeuroStrip® rollout, NeuroNode® expansion, and clinical trials
Rights issue partially underwritten to $1.15 million by major shareholders and partners
Offer closes 15 September 2025, open to Australian and New Zealand shareholders
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Control Bionics (ASX:CBL)
OPEN ARTICLE